News

 

 

Funding: New Awards

Thomas H. Davis
Associate Professor
Cancer Control

  • Janssen Pharmaceuticals
    A randomized controlled study of YONDELIS (Trabectidin) or dacarbazine for the treatment of advanced liposarcoma or leiomyosarcoma
  • Boehringer Ingelheim
    LUX-Head & Neck 2: A randomised, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with Stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma

Marc Ernstoff
Professor
Immunology and Cancer Immunotherapy

  • Prometheus Laboratories Incorporated
    A multi-center study of high dose aldesleukin (Interleukin-2)+ vemurafenib therapy in patients with BRAFV600 mutation positive metastatic melanoma
  • Bristol Myers Squibb
    A randomized, open-label, Phase 3 study of Bms-936558 vs. everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy

Peter Kaufman
Associate Professor
Molecular Therapeutics

  • Nektar
    The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 open-label, randomized, multicenter study of NKTR-102 versus treatment of physician`s choice (TPC) in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

J Marc Pipas
Associate Professor
Molecular Therapeutics

  • Taiho
    Randomized, double-blind, Phase 3 study of TAS-102 plus best supportive care (BSC)versus placebo plus BSC in patients with metastatic colorectal cancer refractory to standard chemotherapies

James R. Rigas
Associate Professor
Molecular Therapeutics

  • Bristol Myers Squibb
    Randomized, multicenter, double-blind, Phase 3 trial comparing the efficacy of Ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin in subjects with Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Gary N. Schwartz
Associate Professor
Molecular Therapeutics
PI/Dept Funding
Tumor Specific Plasma DNA in Breast Cancer

  • PI/Dept Funding
    Patient-derived breast cancer xenografts
  • Merck and Company
    A Phase 2 randomized trial of the combination of ridaforolimus and exemestane, compared to ridaforolimus, dalotuzumab and exemestane in high proliferation, estrogen receptor positive breast cancer patients